Compare OPAL & IBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | OPAL | IBIO |
|---|---|---|
| Founded | 1998 | 2008 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Natural Gas Distribution | Biotechnology: Pharmaceutical Preparations |
| Sector | Utilities | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 58.2M | 52.8M |
| IPO Year | 2021 | 2009 |
| Metric | OPAL | IBIO |
|---|---|---|
| Price | $1.51 | $0.82 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 5 | 9 |
| Target Price | $3.13 | ★ $5.69 |
| AVG Volume (30 Days) | 149.0K | ★ 817.4K |
| Earning Date | 11-09-2026 | 11-16-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 650.00 | 81.71 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $348,975,000.00 | N/A |
| Revenue This Year | $3.57 | N/A |
| Revenue Next Year | $13.13 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 16.34 | N/A |
| 52 Week Low | $1.42 | $0.69 |
| 52 Week High | $2.87 | $3.82 |
| Indicator | OPAL | IBIO |
|---|---|---|
| Relative Strength Index (RSI) | 37.80 | 42.22 |
| Support Level | $1.46 | $0.71 |
| Resistance Level | $2.38 | $1.52 |
| Average True Range (ATR) | 0.09 | 0.06 |
| MACD | 0.01 | 0.02 |
| Stochastic Oscillator | 43.48 | 65.16 |
OPAL Fuels Inc is a fully integrated leader in the capture and conversion of biogas into low-carbon-intensity renewable natural gas and Renewable Power. The company is also engaged in the marketing and distribution of RNG to heavy-duty trucking and other hard-to-decarbonize industrial sectors. The company designs, develops, constructs, operates, and services Fueling Stations for trucking fleets across the country that use natural gas to displace diesel as their transportation fuel. The company derives revenue from the sale of Renewable Power, design, development, construction, and service of Fueling Stations, and sales of RNG produced by OPAL and third parties as pipeline-quality natural gas. The Company has three operating segments: RNG Fuel, Fuel Station Services, and Renewable Power.
iBio Inc is a clinical-stage biotechnology company using Artificial Intelligence (AI) for the development of hard-to-drug precision antibodies for obesity, cardiometabolic, and cardiopulmonary diseases. Its product candidate pipeline includes IBIO-610, a monoclonal antibody designed to block Activin E; IBIO-800, a bispecific antibody program targeting myostatin, growth differentiation factor 11 (GDF11), and Activin A; IBIO-600; Amylin Antibody; and Target 4, in different stages of development, being developed as potential therapies for obesity and cardiometabolic disease. The company operates as one reportable segment, which is that of a biotechnology company leveraging AI and ML for the development of hard-to-drug precision antibodies.